KB Financial Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

KB Financial Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$31K	Buy	348 +118	+51%	+$10.5K	0.01%	305
2023 Q2	$20K	Hold	230	–	–	0.01%	352
2023 Q1	$22K	Hold	230	–	–	0.01%	344
2022 Q4	$24K	Buy	+230	New	+$21.6K	0.01%	333
2021 Q2	–	Sell	-2,081	Closed	-$157K	–	617
2021 Q1	$157K	Buy	+2,081	New	+$170K	0.07%	172

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KB Financial Partners's BMRN Position: Q3 2023 in Review

KB Financial Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 51% in Q3 2023, buying an estimated $10.5K and bringing the position to 348 shares worth $31K. The position accounts for 0.01% of the portfolio, ranked #305.

KB Financial Partners first reported a position in BMRN in Q1 2021 and has held it in 5 quarters since. The position peaked at $157K in Q1 2021. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

KB Financial Partners held 348 shares of BioMarin Pharmaceuticals worth $31K as of Q3 2023.
KB Financial Partners bought 118 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $10.5K.
BioMarin Pharmaceuticals made up 0.01% of KB Financial Partners's portfolio in Q3 2023, its #305 holding.
KB Financial Partners first reported a position in BioMarin Pharmaceuticals in Q1 2021 and has held it in 5 quarters since.
KB Financial Partners's BioMarin Pharmaceuticals position peaked at $157K in Q1 2021.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on KB Financial Partners's 13F filing for Q3 2023, filed 15 Nov 2023.